852324-29-9

Basic information

• Product Name: (S)-1-Methyl-pyrrolidine-2-carbaldehyde
• Synonyms: (S)-1-Methyl-pyrrolidine-2-carbaldehyde;(2S)-1-Methyl-2-Pyrrolidinecarboxaldehyde;(2S)-1-methylpyrrolidine-2-carbaldehyde
• CAS NO: 852324-29-9
• Molecular Formula: C₆H₁₁NO
• Molecular Weight: 113.15764
• Mol File: 852324-29-9.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-1-Methyl-pyrrolidine-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-Methyl-pyrrolidine-2-carbaldehyde(852324-29-9)
• EPA Substance Registry System: (S)-1-Methyl-pyrrolidine-2-carbaldehyde(852324-29-9)

Safety Data

• Hazardous Substances Data: 852324-29-9(Hazardous Substances Data)

Usage

Description

(S)-1-Methyl-pyrrolidine-2-carbaldehyde, also known as (S)-2-formyl-1-methylpyrrolidine, is a colorless liquid chemical compound with the molecular formula C6H11NO, characterized by its punchy odor. It features a chiral center, existing in two enantiomeric forms, (S)and (R)-, with the (S)-enantiomer being favored for its higher biological activity.

Uses

Used in Pharmaceutical Industry:
(S)-1-Methyl-pyrrolidine-2-carbaldehyde is used as an intermediate in the synthesis of various medications for treating conditions such as hypertension, asthma, and allergies due to its higher biological activity in the (S)-enantiomer form.
Used in Fragrance and Flavor Industry:
(S)-1-Methyl-pyrrolidine-2-carbaldehyde is also utilized as a key ingredient in the manufacturing of fragrances and flavors, contributing to the development of new scents and tastes in the market.
Used in Research and Development:
(S)-1-Methyl-pyrrolidine-2-carbaldehyde is employed in research and development for its organic chemistry applications, furthering scientific understanding and innovation in the field.

Upstream product

• 2577-48-2 methyl (2S)-pyrrolidine carboxylate 
• 147-85-3 L-proline 
• 88218-12-6 S-pyrrolidine-2-carbaldehyde 
• 74-88-4 methyl iodide 
• 69610-41-9 Boc-L-Pro-H 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 34381-71-0 (S)-2-hydroxymethyl-1-methylpyrrolidine 
• 27957-91-1 N-Methyl-L-proline Methyl Ester 

Downstream Products

• 1269662-75-0 (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-ethoxyquinazolin-6-yl]-3-[(2S)-1-methylpyrrolidin-2-yl]propan-2-enoylamine 
• 1269662-72-7 (E)-N-[4-[[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]quinazolin-6-yl]-3-[(2S)-1-methylpyrrolidin-2-yl]propan-2-enoylamine 
• 1269662-69-2 (E)-N-[4-[[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-3-[(2S)-1-methylpyrrolidin-2-yl]propan-2-enoylamine 
• 181359-58-0 (7R,8R,8aS)-5-Oxo-8-phenylselanyl-octahydro-indolizine-7-carboxylic acid ethyl ester 
• 639821-08-2 2,6-Bis-[1-((S)-1-methyl-pyrrolidin-2-yl)-meth-(E)-ylidene]-cyclohexanone 

Relevant articles and documents

Efficient synthesis of methyl (S)-4-(1-methylpyrrolidin-2-YL)-3-oxobutanoate as the key intermediate for tropane alkaloid biosynthesis with optically acitve form

Methyl (S)-4-(1-methylpyrrolidin-2-yl)-3-oxobutanoate has been synthesized for enzymatic studies on cyclization enzymes during cocaine biosynthesis in Erythroxylum coca plants. During the present new synthesis, L-proline was first protected with Cbz group and reduced to chiral amino alcohol, which were then followed by Swern oxidation, Wittig reaction and decarboxylative condensation. At the last step, N-methylamino acid precursor was treated with 1,1'-carbonyldiimidazole followed by reacting with methyl potassium malonate to give the 3-oxobutanoate in 54% overall yield. This new strategy has proven to avoid obvious racemization of the L-proline chiral center during the synthesis. In addition, six of the eight synthesis steps were performed via GAP chemistry/technology without the use of column chromatography for purification.

6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

The present disclosure relates to 6-amino quinazoline or 3-cyano quinoline derivatives, preparation processes and pharmaceutical compositions containing them. Specifically, the present disclosure relates to novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by formula (I), or its tautomer, enantiomer, diastereomer, racemate or pharmaceutically acceptable salts thereof, or metabolite, metabolic precursor or prodrug thereof, and the uses for treatment especially for protein kinase inhibitors, in which each substitute group of general formula (I) is as defined in the specification.

6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF

6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof are disclosed. Specifically, the present disclosure discloses novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, and their uses as treatment agents especially as protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification.